Compare Abbott Laboratories (ABT) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Gemini Space Station Inc — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Gemini Space Station Inc trades at $4.15 (market cap $528.49M). The key difference: Abbott Laboratories is far larger — about 315.9× Gemini Space Station Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| ABT | GEMI | |
|---|---|---|
Market Cap | $166.94B | $528.49M |
Sector | Health | Technology |
52-Week High | $136.62 | $32.52 |
52-Week Low | $82.57 | $3.91 |
Enterprise Value | $193.69B | $518.47M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Gemini Space Station (GEMI) trades at $4.41, up 4.26% today, but remains in a bearish technical trend with significant fundamental challenges. The company reported a net loss of $582.81 million in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news includes a $100 million investment from Winklevoss Capital but also multiple class-action lawsuits alleging securities law violations.
The outlook is highly speculative. Analyst consensus suggests modest upside to a $5.95 price target, but persistent losses, legal overhangs, and negative cash flow from operations pose substantial risks. Investment appeal hinges on the company's ability to monetize its super app strategy and achieve profitability, which remains uncertain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
